TEV-'408, an anti-IL-15 antibody, showed promising Phase 1b results in vitiligo, with 42% of patients achieving ≥50% facial repigmentation at 24 weeks and a favorable safety profile. The candidate offers quarterly dosing and potential expansion to other autoimmune diseases.Original document: Teva P…
TEV-'408, an anti-IL-15 antibody, showed promising Phase 1b results in vitiligo, with 42% of patients achieving ≥50% facial repigmentation at 24 weeks and a favorable safety profile. The candidate offers quarterly dosing and potential expansion to other autoimmune diseases.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
